Elisabet Figuerola Bou

Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano P, Pérez-Jaume S, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J.

KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma

Biorxiv 2023. : .

[doi:10.1101/2023.01.24.524910]

Sánchez-Molina S, Figuerola-Bou E, Sánchez-Margalet V, de la Cruz-Merino L, Mora J, de Álava Casado E, García-Domínguez DJ and Hontecillas-Prieto L.

Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies

Cancers 2022. 14(21): . Nº de citas: 6

[doi:10.3390/cancers14215473]

García-Domínguez DJ, Hajji N, López-Alemany R, Sánchez-Molina S, Figuerola-Bou E, Morón Civanto FJ, Rello-Varona S, Andrés-León E, Benito A, Keun HC, Mora J, Tirado ÓM, de Álava E and Hontecillas-Prieto L.

Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1

Oncogene 2022. 41(18): 2638-2650. Nº de citas: 14

[doi:10.1038/s41388-022-02279-w]

García-Domínguez DJ, Hajji N, Sánchez-Molina S, Figuerola-Bou E, de Pablos RM, Espinosa-Oliva AM, Andrés-León E, Terrón-Camero LC, Flores-Campos R, Pascual-Pastó G, Robles MJ, Machado I, Llombart-Bosch A, Magagnoli G, Scotlandi K, Carcaboso AM, Mora J, de Álava E and Hontecillas-Prieto L.

Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma

Oncogene 2021. 40(39): 5843-5853. Nº de citas: 11

[doi:10.1038/s41388-021-01974-4]

Sánchez-Molina S, Figuerola-Bou E, Blanco ME, Sanchez-Jimenez M, Táboas-Outón P, Gomez-Gonzalez S, Ballaré C, García-Domínguez DJ, Prada-Varela E, Hontecillas-Prieto L, Carcaboso AM, Tirado ÓM, Hernandez-Muñoz MI, de Álava E, Lavarino C, Di Croce L and Mora J.

RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis

Science Advances 2020. 6(43): 3058. Nº de citas: 24

[doi:10.1126/sciadv.aba3058]

Hernandez-Muñoz I, Figuerola-Bou E, Sánchez-Molina S, Rodriguez E, Fernández-Mariño AI, Pardo-Pastor C, Bahamonde MI, Fernández-Fernández JM, García-Domínguez DJ, Hontecillas-Prieto L, Lavarino C, Carcaboso AM, de Torres C, Tirado OM, de Alava E and Mora J.

RING1B contributes to Ewing sarcoma development by repressing the Na_V1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein

Oncotarget 2016. 7(29): 46283-46300. Nº de citas: 12

[doi:10.18632/oncotarget.10092]

Figuerola-Bou E.

Un procés reversible: la metilació del DNA en càncer

Treballs de la Societat Catalana de Biologia 2014. 60: 70-71.